Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan Saves 431.5 Billion Yen in Drug Price Cuts, Curbs Social Security Costs: FY2021 Draft Budget
December 21, 2020
- Next New Drug Listing Scheduled for Next April: MHLW
December 21, 2020
- Chuikyo OKs Outline of FY2021 Off-Year Re-Pricing; Only Market Price-Linked Rules to Be Applied
December 21, 2020
- PMDA Reviewing Safety Risks for Pomalyst, MabCampath
December 21, 2020
- Ministers Agree on 5%-Plus Price Discrepancy Line for Off-Year Re-Pricing; 59% Coverage for Innovative Meds, 88% for LLPs, 83% for Gx
December 18, 2020
- Avigan’s COVID-19 Use Up for PAFSC Review on December 21
December 17, 2020
- MHLW Earmarks 3 Billion Yen in FY2020 Extra Budget to Support Construction of API Facilities
December 17, 2020
- Govt Settles on Discrepancy Rate Threshold of “Above 5%” for Off-Year Drug Re-Pricing, 430 Billion Yen Reduction, 60% Coverage for Innovative Meds
December 17, 2020
- Japan Govt Eyes 4-6% Price Discrepancy Threshold for Off-Year Drug Re-Pricing
December 16, 2020
- Avigan to Come Up for PAFSC Review This Month
December 16, 2020
- Govt to Set 2 Million Yen Income Threshold for Elderly Copay Raise
December 16, 2020
- Govt Wants Chuikyo to Work Out Policies on Insurance Coverage for Infertility Treatments in Early 2022
December 16, 2020
- AMED’s Private Information on 1,400 Employees Might Be Leaked due to Unauthorized Access
December 16, 2020
- MHLW Urges Drug Makers to Boost Manufacturing Control after Itraconazole Issue
December 15, 2020
- No Plan to Investigate Efficacy of Japanese Encephalitis Vaccines against COVID-19: Govt
December 15, 2020
- Japan to Prioritize COVID-19 Vaccinations for Doctors, Staffers in Frequent Contact with Infected Patients
December 15, 2020
- Japan Weighs Drug Cost Cut of around 400 Billion Yen in Off-Year Re-Pricing, Expanded Coverage Including Products with Smaller-than-Average Price Gap Too
December 15, 2020
- Off-Year Re-Pricing Should Be Done in “Extremely Limited Scope” If Conducted: LDP Panel
December 14, 2020
- Ono’s Cancer Cachexia Med Clears PAFSC Review after Recommendation Hold
December 14, 2020
- Chuikyo Healthcare Rep Wants Off-Year Re-Pricing Threshold Set at 2 Times-Plus Average Price Gap, Payers Want Further Estimates for Larger Product Coverage
December 14, 2020
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…